Guyasuta Investment Advisors Inc. Sells 4,462 Shares of Becton, Dickinson and Company $BDX

Guyasuta Investment Advisors Inc. decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by 2.8% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 154,195 shares of the medical instruments supplier’s stock after selling 4,462 shares during the quarter. Becton, Dickinson and Company comprises 1.6% of Guyasuta Investment Advisors Inc.’s portfolio, making the stock its 21st biggest holding. Guyasuta Investment Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $27,601,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Maryland Capital Advisors Inc. increased its stake in Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares during the period. Meeder Asset Management Inc. increased its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the period. Bayban bought a new position in Becton, Dickinson and Company in the fourth quarter worth approximately $36,000. Finally, Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth $29,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 2.6%

Shares of NYSE:BDX opened at $193.82 on Friday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $194.34. The business has a 50-day moving average price of $183.74 and a 200-day moving average price of $163.50. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $53.40 billion, a price-to-earnings ratio of 58.38, a PEG ratio of 12.73 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the firm posted $3.68 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were paid a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Weiss Ratings raised Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 28th. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Barclays assumed coverage on Becton, Dickinson and Company in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price objective for the company. Finally, UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $185.07.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 6,906 shares of company stock worth $1,265,855. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.